Cost-effectiveness of particle therapy: Current evidence and future needs

被引:42
|
作者
Pijls-Johannesma, Madelon [1 ]
Pommier, Pascal [2 ]
Lievens, Yolande [3 ]
机构
[1] Univ Med Ctr, Maastricht Radiat Oncol MAASTRO Clin, NL-6229 ET Maastricht, Netherlands
[2] Canc Ctr Leon Berard, Dept Radiat Oncol, Lyon, France
[3] Univ Hosp Gasthuisberg, Dept Radiat Oncol, B-3000 Louvain, Belgium
关键词
Particles; Hadron; Ion; Proton; Radiotherapy; Cost-effectiveness; Reimbursement;
D O I
10.1016/j.radonc.2008.07.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Questions are being raised regarding the cost of particle therapy (PT), and with them criticism that PT is too expensive to allow the expected gain in effectiveness. This paper aims to get more insight in the cost and cost-effectiveness of particle therapy and to discuss a future strategy that allows for critical assessment of this health technology. Material and methods: A systematic literature review based on an earlier published comprehensive review was performed and updated until June 1st 2008. Besides, current business plans of PT projects were examined. Additionally, results retrieved from a cost-simulation tool developed under auspice of the ENLIGHT were discussed. Results: The current literature on cost-effectiveness of PT is scarce, non-comparable, and largely not performed according to standard health technology assessment criteria. Besides, different perspectives for cost evaluations have been used, making it difficult to compare and to determine the relative impact in terms of costs for this new treatment modality. Conclusions: Evidence on the cost-effectiveness of PT is scarce. Adequate reimbursement is necessary to support such innovative yet costly treatments. For now, model-based economic evaluations performed at least from a health care perspective may help us to gain evidence-based insight into cost-effectiveness. (c) 2008 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 89 (2008) 127-134.
引用
收藏
页码:127 / 134
页数:8
相关论文
共 50 条
  • [21] The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment
    Eskazan, Ahmet Emre
    Soysal, Teoman
    LEUKEMIA & LYMPHOMA, 2015, 56 (05) : 1554 - 1555
  • [22] Response to "Future costs and the future of cost-effectiveness analysis"
    Meltzer, David
    JOURNAL OF HEALTH ECONOMICS, 2008, 27 (04) : 822 - 825
  • [23] Aligning meta-regression analyses of cost-effectiveness evidence to policy makers' needs
    Nemzoff, Cassandra
    LANCET GLOBAL HEALTH, 2024, 12 (07): : e1079 - e1080
  • [24] The cost-effectiveness of biopharmaceuticals A look at the evidence
    Wilson, Andrew W.
    Neumann, Peter J.
    MABS, 2012, 4 (02) : 281 - 288
  • [25] Evidence from Cost-Effectiveness Research
    Noyes K.
    Holloway R.G.
    NeuroRX, 2004, 1 (3): : 348 - 355
  • [26] Incorporating future costs in medical cost-effectiveness analysis: Implications for the cost-effectiveness of the treatment of hypertension
    Johannesson, M
    Meltzer, D
    OConor, RM
    MEDICAL DECISION MAKING, 1997, 17 (04) : 382 - 389
  • [27] COST-EFFECTIVENESS OF PHARMACOLOGICAL INTERVENTIONS FOR SMOKING CESSATION: CURRENT EVIDENCE AND POLICY IMPLICATIONS
    Heredia, I
    Valencia, A.
    Bertozzi, S.
    VALUE IN HEALTH, 2009, 12 (07) : A526 - A526
  • [28] Genetic testing for warfarin initiation: A cost-effectiveness analysis based on current evidence
    Meckley, L. M.
    Gudgeon, J. M.
    Anderson, J. L.
    Williams, M. S.
    Veenstra, D. L.
    VALUE IN HEALTH, 2008, 11 (03) : A51 - A51
  • [29] Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study
    Slot, Matilde
    Rasmussen, Thomas Bojer
    Norgaard, Mette
    Larsen, Carsten Schade
    Ehlers, Lars Holger
    PHARMACOECONOMICS-OPEN, 2024, 8 (06) : 847 - 856
  • [30] COST-EFFECTIVENESS OF DABIGATRAN WITH REAL WORLD EFFECTIVENESS EVIDENCE
    de Pouvourville, G.
    Guilmet, C.
    Cohen, A. A.
    Le Dissez, C.
    Luciani, L.
    Le Lay, K.
    VALUE IN HEALTH, 2017, 20 (09) : A399 - A399